T ype 2 diabetes is associated with a cluster of cardiovascular risk factors that together promote macrovascular and microvascular disease. An atherogenic dyslipidaemia, characterised by an increase in serum triglyceride-rich lipoproteins, a decrease in plasma levels of high-density lipoprotein cholesterol (HDL-C) and increased prevalence of small, dense lowdensity lipoprotein (LDL) particles (although LDL-C levels are normal or only modestly elevated), as well as chronic inflammation, play key roles in the pathogenesis of diabetes-related complications. As peroxisome proliferatoractivated receptor α agonists, the fibrates exert an integrated action to favour normalisation of lipid metabolism, cholesterol homeostasis and reverse cholesterol transport, inflammation and haemostasis, suggesting potential efficacy in preventing vascular complications of diabetes. By synergistic therapeutic targeting of abnormalities in lipid metabolism and inflammation, fenofibrate can promote anti-atherogenic effects at the arterial wall, as demonstrated in the Diabetes Atherosclerosis Intervention Study (DAIS), and reduction of total cardiovascular events, as shown in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial. Diabetes Vasc Dis Res 2006;3(suppl 1):S6-S9
Introduction
Type 2 diabetes is characterised by a clustering of cardiovascular risk factors (figure 1), which interact to promote macrovascular and microvascular disease. An integrated therapeutic approach is therefore essential to attenuate the wide spectrum of metabolic, inflammatory and vascular abnormalities and to reduce the associated cardiovascular risk in patients with type 2 diabetes. 1, 2 Diabetic dyslipidaemia A prominent feature of type 2 diabetes is an atherogenic dyslipidaemia, characterised by an increase in triglyceriderich lipoproteins (very low-density lipoproteins [VLDL] and their remnants), a decrease in plasma levels of high-density lipoprotein cholesterol (HDL-C) and an increase in the number of small, dense low-density lipoprotein (LDL) particles, although LDL-C levels may be normal or only modestly elevated. 3 The metabolic basis for this atherogenic phenotype is summarised in figure 2. Insulin resistance increases the mobilisation of free fatty acids (FFAs) from adipose tissue, thereby increasing production of VLDL in the liver; downregulation of lipoprotein lipase expression under these conditions results in reduction of the intravascular catabolism of triglyceride-rich VLDL. As a result, there is a net increase in triglyceride levels, which act as a substrate for cholesteryl ester transfer protein-mediated transfer of cholesteryl ester from HDL. This process favours the production of small, dense LDL particles, which are considered highly atherogenic because of their reduced binding affinity to the LDL receptor, increased susceptibility to oxidation, prolonged plasma residence time, their greater ability to penetrate the arterial wall compared with larger LDL particles, and their elevated binding affinity for matrix proteoglycans leading to intimal retention. [4] [5] [6] [7] Equally, triglyceride-rich small, dense HDL are formed with reduced anti-oxidant and anti-inflammatory properties. 8 In addition, there is a reduction in Atherogenic dyslipidaemia -fasting -postprandial reverse cholesterol transport, the process in which cholesterol is transported from peripheral tissues to the liver for recycling and elimination from the body. 9 Acting together, these metabolic perturbations promote increased deposition of cholesterol within the artery wall and thus favour atherogenesis.
Chronic low-grade inflammation may also play a role in the pathogenesis of endothelial dysfunction and vascular disease in type 2 diabetes. 10 Endothelial dysfunction promotes an increase in the accumulation of lipoproteins in the arterial wall; these subsequently undergo oxidative modification, resulting in increased inflammation and progression of atherosclerotic plaque (figure 3). Increases in inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) are associated with increased risk of atherosclerosis. 11, 12 In addition, elevated levels of plasminogen-activator inhibitor protein-1 (PAI-1) favour development of a prothrombotic state. 13 Given the nature of the atherogenic dyslipidaemia typically associated with type 2 diabetes, the role of lipidmodifying therapy in attenuating diabetes-related macrovascular atherosclerotic disease is attracting increasing interest. Statins are regarded as the cornerstone of lipid-modifying therapy, based on their proven efficacy in reducing plasma levels of LDL-C, triglycerides (TG) and triglyceride-rich VLDL (by up to 35%) but they exert only modest effects on raising HDL-C (typically by less than 10%). 14 The pharmacological profile of the fibrates, specifically their well-established efficacy in reducing TG and their capacity to raise HDL-C levels to a comparable or greater degree than statins, 15, 16 has led to a re-evaluation of their role in reducing vascular risk in patients with type 2 diabetes.
The mode of action of fibrates
The primary mode of action of the fibrates is via activation of the nuclear transcription factor peroxisome proliferatoractivated receptor α (PPARα), a factor that is predominantly expressed in tissues that metabolise fatty acids, such as the liver, kidney, heart and muscle. 16, 17 Following activation by binding of the fibrate, PPARα bind as heterodimers with the retinoid X receptor (RXR), which subsequently recognises and binds to specific PPARα response elements thereby leading to modulation of expression of the target genes influencing lipoprotein and fatty acid metabolism, cholesterol homeostasis, inflammation and haemostasis (figure 4). [16] [17] [18] The relative lipid-lowering potency of fibrates varies depending on the potency and specificity of the individual fibrate for binding to PPARα. Experimental studies using a cell-based transactivation assay show that fenofibrate has higher binding affinity for PPARα than other fibrates such as bezafibrate and clofibrate. 19 Improving atherogenic dyslipidaemia attenuates macrovascular disease Fibrates exert a wide spectrum of lipid-modifying actions which influence the atherogenic dyslipidaemia commonly associated with type 2 diabetes, including reduction of VLDL, VLDL remnants, intermediate-density lipoproteins (IDL), as well as an increase in plasma levels of HDL-C. 17 Evidence for the mechanism of the fibrates, specifically fenofibrate, in attenuating the atherogenic dyslipidaemia associated with type 2 diabetes is provided by recent studies. In one study, 20 treatment with fenofibrate for four months led to a significant reduction in FFA levels compared with control subjects, attributable to an increase in FFA clearance, predominantly via an increase in FFA oxidation in the muscle. In addition, fenofibrate reduced hepatic lipogenesis, resulting in reduction in levels of VLDL-triglyceride, but significantly increased concentrations of ABCA1 mRNA in circulating mononuclear cells, indicative of up-regulation of expression of the lipoprotein transporter protein ABCA1, consistent with stimulation of reverse cholesterol transport. 20 In addition, fibrates modify the quality of lipoprotein particles, most prominently by promoting a shift from small, dense LDL to larger and more buoyant particles, with increased binding affinity for the LDL receptor. 17 Evidence from clinical studies with fenofibrate supports this action. In one small study involving 32 patients with type 2 diabetes, treatment with fenofibrate 200 mg/day for 12 weeks significantly reduced the predominance of small, dense LDL particles (LDL-III) by over 50%, resulting in an LDL phenotype mainly characterised by larger particles (with increases in LDL-I by 64% and LDL-II by 53%, p<0.05). 21 Findings from DAIS 22 in 418 subjects with diabetes provide further support for this effect of fenofibrate. Treatment with fenofibrate for a mean of 39.6 months increased plasma levels of HDL-C, reduced plasma levels of TG, LDL-C and apolipoprotein B (apoB, a measure of the number of circulating atherogenic particles), 22 and significantly increased LDL size (p<0.001); together these changes contributed to a significant reduction in progression of coronary atherosclerosis. 23 A significant association between changes in LDL size and plasma lipoprotein concentrations and anti-atherogenic benefit was demonstrated. Notably, in subjects with low concentrations of LDL-C or apoB, a preponderance of small, dense LDL particles promoted an increase in the progression of coronary atherosclerosis. 23 Fibrates also exert pleiotropic effects in the artery wall. 17 PPARα is involved in the control of the anti-inflammatory response via inhibition of the transcription factor nuclear factor κB (NFκB). 17 Fibrates can attenuate the production of pro-inflammatory stimuli such as IL-6 and prostaglandin, as well as expression of inflammatory proteins of the acute phase, including fibrinogen and CRP. [24] [25] [26] [27] In dyslipidaemic patients (with and without coronary heart disease [CHD]), treatment with fenofibrate significantly reduced circulating concentrations of IL-6, fibrinogen and CRP. 26 Fibrates may also have favourable effects on the coagulation and fibrinolytic systems. For example, fenofibrate has been shown to reduce levels of fibrinogen by up to 20%; though gemfibrozil may increase fibrinogen levels. 28 As fibrinogen is recognised as a major independent risk factor for CHD, 29 a reduction in fibrinogen levels is potentially beneficial for reducing thromboembolic complications of atherosclerosis. Furthermore, fenofibrate has been shown to increase fibrinolysis and to attenuate platelet aggregability. 17 
Effects on microvascular disease
Recent interest has focused on the potential of fenofibrate to impact on microvascular disease associated with type 2 diabetes, specifically retinopathy, nephropathy and neuropathy. Persistent hyperglycaemia in target tissues such as the retina, peripheral nerves and the kidneys promotes oxidative stress, inflammation, increased vascular permeability, endothelial dysfunction and ultimately, tissue damage, principally as a result of the inability of specific cell types in these tissues to regulate intracellular glucose levels fully (figure 5). 30 New data indicate that in individuals with elevated triglycerides and metabolic syndrome, treatment with fenofibrate for eight weeks significantly attenuated the development of endothelial dysfunction, reduced vascular inflam- DIABETES AND VASCULAR DISEASE RESEARCH mation (as shown by decreases in CRP and fibrinogen), and increased adiponectin levels and insulin sensitivity. 31 Together these effects could be expected to reduce glucosemediated vascular damage. Findings from the FIELD trial 32 have provided promising data to suggest that treatment with fenofibrate may improve microangiographic manifestations of diabetes. FIELD was the first large prospective study designed to investigate the effect of treatment with fenofibrate 200mg/day on cardiovascular disease events in 9,795 patients with type 2 diabetes. Overall, about 20% of patients had clinical evidence of microvascular complications at study entry. After a median follow-up of five years, fenofibrate produced significant reductions, compared with placebo, in the need for retinal laser therapy (p=0.0003) and in evolution (lesser progression and more regression) of albuminuria (p=0.002). 32 
Synopsis
As PPARα agonists, fibrates exert an integrated action to favour normalisation of lipid metabolism, cholesterol homeostasis, reverse cholesterol transport, inflammation and haemostasis. Consistent with other fibrates, fenofibrate has well established efficacy in reducing TG and LDL-C concentrations, increasing plasma levels of HDL-C, and promoting a shift from small, dense LDL to larger and more buoyant particles, with increased binding affinity for the LDL receptor. Fenofibrate also exerts pleiotropic effects in the artery wall, influencing endothelial dysfunction, inflammation, and the coagulation and fibrinolytic systems. Together these actions translate into anti-atherogenic effects at the arterial wall, as demonstrated in DAIS, 22 and reduction of microvascular damage and microangiopathic disease, as demonstrated by FIELD. 32 
